GlobeNewsWire
17 Jul 2026, 11:32 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA has released final guidance on psychedelic clinical investigations and planned a public hearing on their therapeutic use. — Clear regulatory guidance reduces uncertainty and lowers the barrier to entry for biotech firms developing psychedelic-based drugs.
+0.60Multiple U.S. government agencies, including the HHS, VA, and FDA, have established new Memoranda of Understanding and collaborative initiatives for neuropsychiatric treatments. — Inter-agency cooperation suggests a systemic federal push to accelerate the adoption and funding of new addiction therapies.
+0.50Clearmind Medicine's lead candidate, CMND-100, is currently in FDA-cleared Phase I/IIa clinical trials for Alcohol Use Disorder at Yale and Johns Hopkins. — Active clinical trials at prestigious institutions provide a concrete catalyst for future valuation increases based on data readouts.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company views new FDA guidance and federal momentum in psychedelic therapies as significant positive regulatory developments for its pipeline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
1h ago
